Bernhardt Zeiher Biography and Net Worth

Dr. Zeiher has more than 20 years of experience in the pharmaceutical industry, participating in the development and approval of 15 products across multiple therapeutic areas. As an Entrada Board member, Dr. Zeiher provides both clinical and regulatory insights as the Company continues to advance our lead programs. He also serves on the Board of Directors for Amylyx Pharmaceuticals and Abeona Therapeutics.

Dr. Zeiher was most recently the Chief Medical Officer at Astellas Pharma. He started at the company in 2010 as Vice President and Therapeutic Area Leader for Inflammation, Immunology and Infectious Diseases. He was promoted to Senior Vice President and Therapeutic Area Head for Immunology, Infectious Diseases and Transplant in 2012. Dr. Zeiher was later named Executive Vice President and Therapeutic Area Head when his responsibilities expanded to include the company's development operations and clinical pharmacology departments. He was promoted to President of Development in 2015, and Chief Medical Officer in 2018. Prior to joining Astellas, Dr. Zeiher served as Vice President of the Inflammation and Immunology Therapeutic Area at Pfizer and Medical Director for Inflammation and Immunology at Eli Lilly and Company.

Dr. Zeiher holds an MD from the Case Western Reserve University School of Medicine and a BS in Biology from the University of Toledo. He completed an internal medicine residency at University Hospitals of Cleveland as well as a fellowship in Pulmonary and Critical Care Medicine at University of Iowa Hospitals and Clinics. He served on the Board of Directors for TransCelerate BioPharma Inc. from 2014 to 2022 and the Biotechnology Innovation Organization (BIO) from 2019 to 2021. Dr. Zeiher is a Fellow in the American College of Physicians and the American College of Chest Physicians, which is awarded to those who demonstrate knowledge and compassion towards teaching others.